Global Single-target Anti-VEGF Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Single-target Anti-VEGF Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Single-target anti-VEGF drugs are medications designed to specifically block the action of vascular endothelial growth factor(VEGF)in the eye.VEGF plays a crucial role in promoting the growth of abnormal blood vessels,which can lead to vision-threatening conditions such as wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema.
This report is a detailed and comprehensive analysis for global Single-target Anti-VEGF Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Single-target anti-VEGF drugs are medications designed to specifically block the action of vascular endothelial growth factor(VEGF)in the eye.VEGF plays a crucial role in promoting the growth of abnormal blood vessels,which can lead to vision-threatening conditions such as wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema.
This report is a detailed and comprehensive analysis for global Single-target Anti-VEGF Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
- Global Single-target Anti-VEGF Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
- Global Single-target Anti-VEGF Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
- Global Single-target Anti-VEGF Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
- Global Single-target Anti-VEGF Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Single-target Anti-VEGF Drugs
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
- This report profiles key players in the global Single-target Anti-VEGF Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, Biocon Biologics, Chengdu Kanghong Pharmaceutical, etc.
- This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Single-target Anti-VEGF Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.Market segment by Type
- Aflibercept
- Conbercept
- Ranibizumab
- Brolucizumab
- Faricimab
- Other
Market segment by Application
- Age-related Macular Degeneration
- Diabetic Retinopathy
- Other
Major players covered
- Roche
- Novartis
- Coherus BioSciences
- Regeneron Pharmaceuticals
- Samsung Bioepis
- Biocon Biologics
- Chengdu Kanghong Pharmaceutical
Market segment by region, regional analysis covers
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
- Chapter 1, to describe Single-target Anti-VEGF Drugs product scope, market overview, market estimation caveats and base year.
- Chapter 2, to profile the top manufacturers of Single-target Anti-VEGF Drugs, with price, sales quantity, revenue, and global market share of Single-target Anti-VEGF Drugs from 2021 to 2026.
- Chapter 3, the Single-target Anti-VEGF Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
- Chapter 4, the Single-target Anti-VEGF Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
- Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
- Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Single-target Anti-VEGF Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
- Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
- Chapter 13, the key raw materials and key suppliers, and industry chain of Single-target Anti-VEGF Drugs.
- Chapter 14 and 15, to describe Single-target Anti-VEGF Drugs sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Single-target Anti-VEGF Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Aflibercept
1.3.3 Conbercept
1.3.4 Ranibizumab
1.3.5 Brolucizumab
1.3.6 Faricimab
1.3.7 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Single-target Anti-VEGF Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.4.2 Age-related Macular Degeneration
1.4.3 Diabetic Retinopathy
1.4.4 Other
1.5 Global Single-target Anti-VEGF Drugs Market Size & Forecast
1.5.1 Global Single-target Anti-VEGF Drugs Consumption Value (2021 & 2025 & 2032)
1.5.2 Global Single-target Anti-VEGF Drugs Sales Quantity (2021-2032)
1.5.3 Global Single-target Anti-VEGF Drugs Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Single-target Anti-VEGF Drugs Product and Services
2.1.4 Roche Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Roche Recent Developments/Updates
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Single-target Anti-VEGF Drugs Product and Services
2.2.4 Novartis Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Novartis Recent Developments/Updates
2.3 Coherus BioSciences
2.3.1 Coherus BioSciences Details
2.3.2 Coherus BioSciences Major Business
2.3.3 Coherus BioSciences Single-target Anti-VEGF Drugs Product and Services
2.3.4 Coherus BioSciences Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Coherus BioSciences Recent Developments/Updates
2.4 Regeneron Pharmaceuticals
2.4.1 Regeneron Pharmaceuticals Details
2.4.2 Regeneron Pharmaceuticals Major Business
2.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product and Services
2.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Regeneron Pharmaceuticals Recent Developments/Updates
2.5 Samsung Bioepis
2.5.1 Samsung Bioepis Details
2.5.2 Samsung Bioepis Major Business
2.5.3 Samsung Bioepis Single-target Anti-VEGF Drugs Product and Services
2.5.4 Samsung Bioepis Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Samsung Bioepis Recent Developments/Updates
2.6 Biocon Biologics
2.6.1 Biocon Biologics Details
2.6.2 Biocon Biologics Major Business
2.6.3 Biocon Biologics Single-target Anti-VEGF Drugs Product and Services
2.6.4 Biocon Biologics Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Biocon Biologics Recent Developments/Updates
2.7 Chengdu Kanghong Pharmaceutical
2.7.1 Chengdu Kanghong Pharmaceutical Details
2.7.2 Chengdu Kanghong Pharmaceutical Major Business
2.7.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product and Services
2.7.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: SINGLE-TARGET ANTI-VEGF DRUGS BY MANUFACTURER
3.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Manufacturer (2021-2026)
3.2 Global Single-target Anti-VEGF Drugs Revenue by Manufacturer (2021-2026)
3.3 Global Single-target Anti-VEGF Drugs Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Single-target Anti-VEGF Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Single-target Anti-VEGF Drugs Manufacturer Market Share in 2025
3.4.3 Top 6 Single-target Anti-VEGF Drugs Manufacturer Market Share in 2025
3.5 Single-target Anti-VEGF Drugs Market: Overall Company Footprint Analysis
3.5.1 Single-target Anti-VEGF Drugs Market: Region Footprint
3.5.2 Single-target Anti-VEGF Drugs Market: Company Product Type Footprint
3.5.3 Single-target Anti-VEGF Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Single-target Anti-VEGF Drugs Market Size by Region
4.1.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Region (2021-2032)
4.1.2 Global Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2032)
4.1.3 Global Single-target Anti-VEGF Drugs Average Price by Region (2021-2032)
4.2 North America Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
4.3 Europe Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
4.4 Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
4.5 South America Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
4.6 Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
5.2 Global Single-target Anti-VEGF Drugs Consumption Value by Type (2021-2032)
5.3 Global Single-target Anti-VEGF Drugs Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
6.2 Global Single-target Anti-VEGF Drugs Consumption Value by Application (2021-2032)
6.3 Global Single-target Anti-VEGF Drugs Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
7.2 North America Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
7.3 North America Single-target Anti-VEGF Drugs Market Size by Country
7.3.1 North America Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
7.3.2 North America Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
8.2 Europe Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
8.3 Europe Single-target Anti-VEGF Drugs Market Size by Country
8.3.1 Europe Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
8.3.2 Europe Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Single-target Anti-VEGF Drugs Market Size by Region
9.3.1 Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
10.2 South America Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
10.3 South America Single-target Anti-VEGF Drugs Market Size by Country
10.3.1 South America Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
10.3.2 South America Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Single-target Anti-VEGF Drugs Market Size by Country
11.3.1 Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Single-target Anti-VEGF Drugs Market Drivers
12.2 Single-target Anti-VEGF Drugs Market Restraints
12.3 Single-target Anti-VEGF Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Single-target Anti-VEGF Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Single-target Anti-VEGF Drugs
13.3 Single-target Anti-VEGF Drugs Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Single-target Anti-VEGF Drugs Typical Distributors
14.3 Single-target Anti-VEGF Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Single-target Anti-VEGF Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Aflibercept
1.3.3 Conbercept
1.3.4 Ranibizumab
1.3.5 Brolucizumab
1.3.6 Faricimab
1.3.7 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Single-target Anti-VEGF Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.4.2 Age-related Macular Degeneration
1.4.3 Diabetic Retinopathy
1.4.4 Other
1.5 Global Single-target Anti-VEGF Drugs Market Size & Forecast
1.5.1 Global Single-target Anti-VEGF Drugs Consumption Value (2021 & 2025 & 2032)
1.5.2 Global Single-target Anti-VEGF Drugs Sales Quantity (2021-2032)
1.5.3 Global Single-target Anti-VEGF Drugs Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Single-target Anti-VEGF Drugs Product and Services
2.1.4 Roche Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Roche Recent Developments/Updates
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Single-target Anti-VEGF Drugs Product and Services
2.2.4 Novartis Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Novartis Recent Developments/Updates
2.3 Coherus BioSciences
2.3.1 Coherus BioSciences Details
2.3.2 Coherus BioSciences Major Business
2.3.3 Coherus BioSciences Single-target Anti-VEGF Drugs Product and Services
2.3.4 Coherus BioSciences Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Coherus BioSciences Recent Developments/Updates
2.4 Regeneron Pharmaceuticals
2.4.1 Regeneron Pharmaceuticals Details
2.4.2 Regeneron Pharmaceuticals Major Business
2.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product and Services
2.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Regeneron Pharmaceuticals Recent Developments/Updates
2.5 Samsung Bioepis
2.5.1 Samsung Bioepis Details
2.5.2 Samsung Bioepis Major Business
2.5.3 Samsung Bioepis Single-target Anti-VEGF Drugs Product and Services
2.5.4 Samsung Bioepis Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Samsung Bioepis Recent Developments/Updates
2.6 Biocon Biologics
2.6.1 Biocon Biologics Details
2.6.2 Biocon Biologics Major Business
2.6.3 Biocon Biologics Single-target Anti-VEGF Drugs Product and Services
2.6.4 Biocon Biologics Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Biocon Biologics Recent Developments/Updates
2.7 Chengdu Kanghong Pharmaceutical
2.7.1 Chengdu Kanghong Pharmaceutical Details
2.7.2 Chengdu Kanghong Pharmaceutical Major Business
2.7.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product and Services
2.7.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: SINGLE-TARGET ANTI-VEGF DRUGS BY MANUFACTURER
3.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Manufacturer (2021-2026)
3.2 Global Single-target Anti-VEGF Drugs Revenue by Manufacturer (2021-2026)
3.3 Global Single-target Anti-VEGF Drugs Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Single-target Anti-VEGF Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Single-target Anti-VEGF Drugs Manufacturer Market Share in 2025
3.4.3 Top 6 Single-target Anti-VEGF Drugs Manufacturer Market Share in 2025
3.5 Single-target Anti-VEGF Drugs Market: Overall Company Footprint Analysis
3.5.1 Single-target Anti-VEGF Drugs Market: Region Footprint
3.5.2 Single-target Anti-VEGF Drugs Market: Company Product Type Footprint
3.5.3 Single-target Anti-VEGF Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Single-target Anti-VEGF Drugs Market Size by Region
4.1.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Region (2021-2032)
4.1.2 Global Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2032)
4.1.3 Global Single-target Anti-VEGF Drugs Average Price by Region (2021-2032)
4.2 North America Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
4.3 Europe Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
4.4 Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
4.5 South America Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
4.6 Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
5.2 Global Single-target Anti-VEGF Drugs Consumption Value by Type (2021-2032)
5.3 Global Single-target Anti-VEGF Drugs Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
6.2 Global Single-target Anti-VEGF Drugs Consumption Value by Application (2021-2032)
6.3 Global Single-target Anti-VEGF Drugs Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
7.2 North America Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
7.3 North America Single-target Anti-VEGF Drugs Market Size by Country
7.3.1 North America Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
7.3.2 North America Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
8.2 Europe Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
8.3 Europe Single-target Anti-VEGF Drugs Market Size by Country
8.3.1 Europe Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
8.3.2 Europe Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Single-target Anti-VEGF Drugs Market Size by Region
9.3.1 Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
10.2 South America Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
10.3 South America Single-target Anti-VEGF Drugs Market Size by Country
10.3.1 South America Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
10.3.2 South America Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Single-target Anti-VEGF Drugs Market Size by Country
11.3.1 Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Single-target Anti-VEGF Drugs Market Drivers
12.2 Single-target Anti-VEGF Drugs Market Restraints
12.3 Single-target Anti-VEGF Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Single-target Anti-VEGF Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Single-target Anti-VEGF Drugs
13.3 Single-target Anti-VEGF Drugs Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Single-target Anti-VEGF Drugs Typical Distributors
14.3 Single-target Anti-VEGF Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Single-target Anti-VEGF Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Single-target Anti-VEGF Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Roche Basic Information, Manufacturing Base and Competitors
Table 4. Roche Major Business
Table 5. Roche Single-target Anti-VEGF Drugs Product and Services
Table 6. Roche Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 7. Roche Recent Developments/Updates
Table 8. Novartis Basic Information, Manufacturing Base and Competitors
Table 9. Novartis Major Business
Table 10. Novartis Single-target Anti-VEGF Drugs Product and Services
Table 11. Novartis Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 12. Novartis Recent Developments/Updates
Table 13. Coherus BioSciences Basic Information, Manufacturing Base and Competitors
Table 14. Coherus BioSciences Major Business
Table 15. Coherus BioSciences Single-target Anti-VEGF Drugs Product and Services
Table 16. Coherus BioSciences Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 17. Coherus BioSciences Recent Developments/Updates
Table 18. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Regeneron Pharmaceuticals Major Business
Table 20. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product and Services
Table 21. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 22. Regeneron Pharmaceuticals Recent Developments/Updates
Table 23. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 24. Samsung Bioepis Major Business
Table 25. Samsung Bioepis Single-target Anti-VEGF Drugs Product and Services
Table 26. Samsung Bioepis Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 27. Samsung Bioepis Recent Developments/Updates
Table 28. Biocon Biologics Basic Information, Manufacturing Base and Competitors
Table 29. Biocon Biologics Major Business
Table 30. Biocon Biologics Single-target Anti-VEGF Drugs Product and Services
Table 31. Biocon Biologics Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 32. Biocon Biologics Recent Developments/Updates
Table 33. Chengdu Kanghong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 34. Chengdu Kanghong Pharmaceutical Major Business
Table 35. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product and Services
Table 36. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 37. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 38. Global Single-target Anti-VEGF Drugs Sales Quantity by Manufacturer (2021-2026) & (K Units)
Table 39. Global Single-target Anti-VEGF Drugs Revenue by Manufacturer (2021-2026) & (USD Million)
Table 40. Global Single-target Anti-VEGF Drugs Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 41. Market Position of Manufacturers in Single-target Anti-VEGF Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 42. Head Office and Single-target Anti-VEGF Drugs Production Site of Key Manufacturer
Table 43. Single-target Anti-VEGF Drugs Market: Company Product Type Footprint
Table 44. Single-target Anti-VEGF Drugs Market: Company Product Application Footprint
Table 45. Single-target Anti-VEGF Drugs New Market Entrants and Barriers to Market Entry
Table 46. Single-target Anti-VEGF Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 47. Global Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 48. Global Single-target Anti-VEGF Drugs Sales Quantity by Region (2021-2026) & (K Units)
Table 49. Global Single-target Anti-VEGF Drugs Sales Quantity by Region (2027-2032) & (K Units)
Table 50. Global Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 51. Global Single-target Anti-VEGF Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 52. Global Single-target Anti-VEGF Drugs Average Price by Region (2021-2026) & (US$/Unit)
Table 53. Global Single-target Anti-VEGF Drugs Average Price by Region (2027-2032) & (US$/Unit)
Table 54. Global Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 55. Global Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 56. Global Single-target Anti-VEGF Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 57. Global Single-target Anti-VEGF Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 58. Global Single-target Anti-VEGF Drugs Average Price by Type (2021-2026) & (US$/Unit)
Table 59. Global Single-target Anti-VEGF Drugs Average Price by Type (2027-2032) & (US$/Unit)
Table 60. Global Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 61. Global Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 62. Global Single-target Anti-VEGF Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 63. Global Single-target Anti-VEGF Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 64. Global Single-target Anti-VEGF Drugs Average Price by Application (2021-2026) & (US$/Unit)
Table 65. Global Single-target Anti-VEGF Drugs Average Price by Application (2027-2032) & (US$/Unit)
Table 66. North America Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 67. North America Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 68. North America Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 69. North America Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 70. North America Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2026) & (K Units)
Table 71. North America Single-target Anti-VEGF Drugs Sales Quantity by Country (2027-2032) & (K Units)
Table 72. North America Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 73. North America Single-target Anti-VEGF Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 74. Europe Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 75. Europe Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 76. Europe Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 77. Europe Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 78. Europe Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2026) & (K Units)
Table 79. Europe Single-target Anti-VEGF Drugs Sales Quantity by Country (2027-2032) & (K Units)
Table 80. Europe Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 81. Europe Single-target Anti-VEGF Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 82. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 83. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 84. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 85. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 86. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Region (2021-2026) & (K Units)
Table 87. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Region (2027-2032) & (K Units)
Table 88. Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 89. Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 90. South America Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 91. South America Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 92. South America Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 93. South America Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 94. South America Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2026) & (K Units)
Table 95. South America Single-target Anti-VEGF Drugs Sales Quantity by Country (2027-2032) & (K Units)
Table 96. South America Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 97. South America Single-target Anti-VEGF Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 98. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 99. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 100. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 101. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 102. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2026) & (K Units)
Table 103. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Country (2027-2032) & (K Units)
Table 104. Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 105. Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 106. Single-target Anti-VEGF Drugs Raw Material
Table 107. Key Manufacturers of Single-target Anti-VEGF Drugs Raw Materials
Table 108. Single-target Anti-VEGF Drugs Typical Distributors
Table 109. Single-target Anti-VEGF Drugs Typical Customers
Table 1. Global Single-target Anti-VEGF Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Single-target Anti-VEGF Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Roche Basic Information, Manufacturing Base and Competitors
Table 4. Roche Major Business
Table 5. Roche Single-target Anti-VEGF Drugs Product and Services
Table 6. Roche Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 7. Roche Recent Developments/Updates
Table 8. Novartis Basic Information, Manufacturing Base and Competitors
Table 9. Novartis Major Business
Table 10. Novartis Single-target Anti-VEGF Drugs Product and Services
Table 11. Novartis Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 12. Novartis Recent Developments/Updates
Table 13. Coherus BioSciences Basic Information, Manufacturing Base and Competitors
Table 14. Coherus BioSciences Major Business
Table 15. Coherus BioSciences Single-target Anti-VEGF Drugs Product and Services
Table 16. Coherus BioSciences Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 17. Coherus BioSciences Recent Developments/Updates
Table 18. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Regeneron Pharmaceuticals Major Business
Table 20. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product and Services
Table 21. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 22. Regeneron Pharmaceuticals Recent Developments/Updates
Table 23. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 24. Samsung Bioepis Major Business
Table 25. Samsung Bioepis Single-target Anti-VEGF Drugs Product and Services
Table 26. Samsung Bioepis Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 27. Samsung Bioepis Recent Developments/Updates
Table 28. Biocon Biologics Basic Information, Manufacturing Base and Competitors
Table 29. Biocon Biologics Major Business
Table 30. Biocon Biologics Single-target Anti-VEGF Drugs Product and Services
Table 31. Biocon Biologics Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 32. Biocon Biologics Recent Developments/Updates
Table 33. Chengdu Kanghong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 34. Chengdu Kanghong Pharmaceutical Major Business
Table 35. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product and Services
Table 36. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 37. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 38. Global Single-target Anti-VEGF Drugs Sales Quantity by Manufacturer (2021-2026) & (K Units)
Table 39. Global Single-target Anti-VEGF Drugs Revenue by Manufacturer (2021-2026) & (USD Million)
Table 40. Global Single-target Anti-VEGF Drugs Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 41. Market Position of Manufacturers in Single-target Anti-VEGF Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 42. Head Office and Single-target Anti-VEGF Drugs Production Site of Key Manufacturer
Table 43. Single-target Anti-VEGF Drugs Market: Company Product Type Footprint
Table 44. Single-target Anti-VEGF Drugs Market: Company Product Application Footprint
Table 45. Single-target Anti-VEGF Drugs New Market Entrants and Barriers to Market Entry
Table 46. Single-target Anti-VEGF Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 47. Global Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 48. Global Single-target Anti-VEGF Drugs Sales Quantity by Region (2021-2026) & (K Units)
Table 49. Global Single-target Anti-VEGF Drugs Sales Quantity by Region (2027-2032) & (K Units)
Table 50. Global Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 51. Global Single-target Anti-VEGF Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 52. Global Single-target Anti-VEGF Drugs Average Price by Region (2021-2026) & (US$/Unit)
Table 53. Global Single-target Anti-VEGF Drugs Average Price by Region (2027-2032) & (US$/Unit)
Table 54. Global Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 55. Global Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 56. Global Single-target Anti-VEGF Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 57. Global Single-target Anti-VEGF Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 58. Global Single-target Anti-VEGF Drugs Average Price by Type (2021-2026) & (US$/Unit)
Table 59. Global Single-target Anti-VEGF Drugs Average Price by Type (2027-2032) & (US$/Unit)
Table 60. Global Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 61. Global Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 62. Global Single-target Anti-VEGF Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 63. Global Single-target Anti-VEGF Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 64. Global Single-target Anti-VEGF Drugs Average Price by Application (2021-2026) & (US$/Unit)
Table 65. Global Single-target Anti-VEGF Drugs Average Price by Application (2027-2032) & (US$/Unit)
Table 66. North America Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 67. North America Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 68. North America Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 69. North America Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 70. North America Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2026) & (K Units)
Table 71. North America Single-target Anti-VEGF Drugs Sales Quantity by Country (2027-2032) & (K Units)
Table 72. North America Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 73. North America Single-target Anti-VEGF Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 74. Europe Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 75. Europe Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 76. Europe Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 77. Europe Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 78. Europe Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2026) & (K Units)
Table 79. Europe Single-target Anti-VEGF Drugs Sales Quantity by Country (2027-2032) & (K Units)
Table 80. Europe Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 81. Europe Single-target Anti-VEGF Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 82. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 83. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 84. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 85. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 86. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Region (2021-2026) & (K Units)
Table 87. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Region (2027-2032) & (K Units)
Table 88. Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 89. Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 90. South America Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 91. South America Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 92. South America Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 93. South America Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 94. South America Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2026) & (K Units)
Table 95. South America Single-target Anti-VEGF Drugs Sales Quantity by Country (2027-2032) & (K Units)
Table 96. South America Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 97. South America Single-target Anti-VEGF Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 98. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2026) & (K Units)
Table 99. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Type (2027-2032) & (K Units)
Table 100. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2026) & (K Units)
Table 101. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Application (2027-2032) & (K Units)
Table 102. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2026) & (K Units)
Table 103. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Country (2027-2032) & (K Units)
Table 104. Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 105. Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 106. Single-target Anti-VEGF Drugs Raw Material
Table 107. Key Manufacturers of Single-target Anti-VEGF Drugs Raw Materials
Table 108. Single-target Anti-VEGF Drugs Typical Distributors
Table 109. Single-target Anti-VEGF Drugs Typical Customers
LIST OF FIGURES
Figure 1. Single-target Anti-VEGF Drugs Picture
Figure 2. Global Single-target Anti-VEGF Drugs Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type in 2025
Figure 4. Aflibercept Examples
Figure 5. Conbercept Examples
Figure 6. Ranibizumab Examples
Figure 7. Brolucizumab Examples
Figure 8. Faricimab Examples
Figure 9. Other Examples
Figure 10. Global Single-target Anti-VEGF Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application in 2025
Figure 12. Age-related Macular Degeneration Examples
Figure 13. Diabetic Retinopathy Examples
Figure 14. Other Examples
Figure 15. Global Single-target Anti-VEGF Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 16. Global Single-target Anti-VEGF Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 17. Global Single-target Anti-VEGF Drugs Sales Quantity (2021-2032) & (K Units)
Figure 18. Global Single-target Anti-VEGF Drugs Price (2021-2032) & (US$/Unit)
Figure 19. Global Single-target Anti-VEGF Drugs Sales Quantity Market Share by Manufacturer in 2025
Figure 20. Global Single-target Anti-VEGF Drugs Revenue Market Share by Manufacturer in 2025
Figure 21. Producer Shipments of Single-target Anti-VEGF Drugs by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 22. Top 3 Single-target Anti-VEGF Drugs Manufacturer (Revenue) Market Share in 2025
Figure 23. Top 6 Single-target Anti-VEGF Drugs Manufacturer (Revenue) Market Share in 2025
Figure 24. Global Single-target Anti-VEGF Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 25. Global Single-target Anti-VEGF Drugs Consumption Value Market Share by Region (2021-2032)
Figure 26. North America Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 27. Europe Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 28. Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 29. South America Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 30. Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 31. Global Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 32. Global Single-target Anti-VEGF Drugs Consumption Value Market Share by Type (2021-2032)
Figure 33. Global Single-target Anti-VEGF Drugs Average Price by Type (2021-2032) & (US$/Unit)
Figure 34. Global Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 35. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2032)
Figure 36. Global Single-target Anti-VEGF Drugs Average Price by Application (2021-2032) & (US$/Unit)
Figure 37. North America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 38. North America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 39. North America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 40. North America Single-target Anti-VEGF Drugs Consumption Value Market Share by Country (2021-2032)
Figure 41. United States Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 42. Canada Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 43. Mexico Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 44. Europe Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 45. Europe Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 46. Europe Single-target Anti-VEGF Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 47. Europe Single-target Anti-VEGF Drugs Consumption Value Market Share by Country (2021-2032)
Figure 48. Germany Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 49. France Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 50. United Kingdom Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 51. Russia Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 52. Italy Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 53. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 54. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 55. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 56. Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value Market Share by Region (2021-2032)
Figure 57. China Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 58. Japan Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 59. South Korea Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 60. India Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 61. Southeast Asia Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. Australia Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. South America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 64. South America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 65. South America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 66. South America Single-target Anti-VEGF Drugs Consumption Value Market Share by Country (2021-2032)
Figure 67. Brazil Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 68. Argentina Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 69. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 70. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 71. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 72. Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value Market Share by Country (2021-2032)
Figure 73. Turkey Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 74. Egypt Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 75. Saudi Arabia Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 76. South Africa Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. Single-target Anti-VEGF Drugs Market Drivers
Figure 78. Single-target Anti-VEGF Drugs Market Restraints
Figure 79. Single-target Anti-VEGF Drugs Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Single-target Anti-VEGF Drugs in 2025
Figure 82. Manufacturing Process Analysis of Single-target Anti-VEGF Drugs
Figure 83. Single-target Anti-VEGF Drugs Industrial Chain
Figure 84. Sales Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source
Figure 1. Single-target Anti-VEGF Drugs Picture
Figure 2. Global Single-target Anti-VEGF Drugs Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type in 2025
Figure 4. Aflibercept Examples
Figure 5. Conbercept Examples
Figure 6. Ranibizumab Examples
Figure 7. Brolucizumab Examples
Figure 8. Faricimab Examples
Figure 9. Other Examples
Figure 10. Global Single-target Anti-VEGF Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application in 2025
Figure 12. Age-related Macular Degeneration Examples
Figure 13. Diabetic Retinopathy Examples
Figure 14. Other Examples
Figure 15. Global Single-target Anti-VEGF Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 16. Global Single-target Anti-VEGF Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 17. Global Single-target Anti-VEGF Drugs Sales Quantity (2021-2032) & (K Units)
Figure 18. Global Single-target Anti-VEGF Drugs Price (2021-2032) & (US$/Unit)
Figure 19. Global Single-target Anti-VEGF Drugs Sales Quantity Market Share by Manufacturer in 2025
Figure 20. Global Single-target Anti-VEGF Drugs Revenue Market Share by Manufacturer in 2025
Figure 21. Producer Shipments of Single-target Anti-VEGF Drugs by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 22. Top 3 Single-target Anti-VEGF Drugs Manufacturer (Revenue) Market Share in 2025
Figure 23. Top 6 Single-target Anti-VEGF Drugs Manufacturer (Revenue) Market Share in 2025
Figure 24. Global Single-target Anti-VEGF Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 25. Global Single-target Anti-VEGF Drugs Consumption Value Market Share by Region (2021-2032)
Figure 26. North America Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 27. Europe Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 28. Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 29. South America Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 30. Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 31. Global Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 32. Global Single-target Anti-VEGF Drugs Consumption Value Market Share by Type (2021-2032)
Figure 33. Global Single-target Anti-VEGF Drugs Average Price by Type (2021-2032) & (US$/Unit)
Figure 34. Global Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 35. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2032)
Figure 36. Global Single-target Anti-VEGF Drugs Average Price by Application (2021-2032) & (US$/Unit)
Figure 37. North America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 38. North America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 39. North America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 40. North America Single-target Anti-VEGF Drugs Consumption Value Market Share by Country (2021-2032)
Figure 41. United States Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 42. Canada Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 43. Mexico Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 44. Europe Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 45. Europe Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 46. Europe Single-target Anti-VEGF Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 47. Europe Single-target Anti-VEGF Drugs Consumption Value Market Share by Country (2021-2032)
Figure 48. Germany Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 49. France Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 50. United Kingdom Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 51. Russia Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 52. Italy Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 53. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 54. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 55. Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 56. Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value Market Share by Region (2021-2032)
Figure 57. China Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 58. Japan Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 59. South Korea Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 60. India Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 61. Southeast Asia Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. Australia Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. South America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 64. South America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 65. South America Single-target Anti-VEGF Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 66. South America Single-target Anti-VEGF Drugs Consumption Value Market Share by Country (2021-2032)
Figure 67. Brazil Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 68. Argentina Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 69. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 70. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 71. Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 72. Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value Market Share by Country (2021-2032)
Figure 73. Turkey Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 74. Egypt Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 75. Saudi Arabia Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 76. South Africa Single-target Anti-VEGF Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. Single-target Anti-VEGF Drugs Market Drivers
Figure 78. Single-target Anti-VEGF Drugs Market Restraints
Figure 79. Single-target Anti-VEGF Drugs Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Single-target Anti-VEGF Drugs in 2025
Figure 82. Manufacturing Process Analysis of Single-target Anti-VEGF Drugs
Figure 83. Single-target Anti-VEGF Drugs Industrial Chain
Figure 84. Sales Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source
